**Rapid Communication**

**In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis**

Andreas Weber, Wolfgang Huber, Klaus Kamereck, Philipp Winkle, Petra Voland, Hans Weidenbach, Roland M Schmid, Christian Prinz

**Abstract**

**AIM:** To analyze the *in vitro* activity of moxifloxacin and piperacillin/sulbactam against pathogens isolated from patients with acute cholangitis.

**METHODS:** In this prospective study a total of 65 patients with acute cholangitis due to biliary stone obstruction (*n* = 7), benign biliary stricture (*n* = 16), and malignant biliary stricture (*n* = 42) were investigated with regard to spectrum of bacterial infection and antibiotic resistance. Pathogens were isolated from bile cultures in all study patients. In 22 febrile patients, blood cultures were also obtained. *In vitro* activity of moxifloxacin and piperacillin/sulbactam was determined by agar diffusion.

**RESULTS:** Thirty-one out of 65 patients had positive bile and/or blood cultures. In 31 patients, 63 isolates with 17 different species were identified. The predominant strains were *Enterococcus* species (26/63), *E.coli* (13/63) and *Klebsiella* species (8/63). A comparable *in vitro* activity of moxifloxacin and piperacillin/sulbactam was observed for *E.coli* and *Klebsiella* species. In contrast, *Enterococcus* species had higher resistances towards moxifloxacin. Overall bacteria showed antibiotic resistances *in vitro* of 34.9% for piperacillin/sulbactam and 36.5% for moxifloxacin.

**CONCLUSION:** *Enterococcus* species, *E.coli* and *Klebsiella* species were the most common bacteria isolated from bile and/or blood from patients with acute cholangitis. Overall, a mixed infection with several species was observed, and bacteria showed a comparable *in vitro* activity for piperacillin/sulbactam and moxifloxacin.

© 2008 The WJG Press. All rights reserved.

**Key words:** Cholangitis; Acute cholangitis; Endoscopy; Antibiotics; Moxifloxacin; Piperacillin; Sulbactam; Biliary stricture; Resistance; Bacterial pathogens

**Peer reviewers:** Dr. Pietro Invernizzi, Department of Medicine, Surgery and Dentistry, University of Milan, Milan 20142, Italy; Sharon DeMorrow, Assistant Professor, Research and Education/Medicine, Scott and White Hospital, Temple 76504, United States

Weber A, Huber W, Kamereck K, Winkle P, Voland P, Weidenbach H, Schmid RM, Prinz C. *In vitro* activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis. *World J Gastroenterol* 2008; 14(20): 3174-3178 Available from: URL: http://www.wjgnet.com/1007-9327/14/3174.asp DOI: http://dx.doi.org/10.3748/wjg.14.3174

**INTRODUCTION**

Acute cholangitis, first described by Charcot in 1877 is a frequent and potentially serious complication in patients with bile duct obstruction. Ductal obstruction leads to a raised intrabiliary pressure with cholangiovenous reflux and bacteremia, which may progress to sepsicaemia[1]. Ductal stones, benign or malignant biliary strictures are reasons for the obstruction. Biliary decompression by endoscopic or percutaneous transhepatic procedures and selection of appropriate antibiotics are crucial in the therapy of these patients[2-3]. The efficacy of antibiotics in the treatment of biliary infections depends on the microbiological activity against the most common pathogens and the excretion of the antibacterial agents in the obstructed biliary tract. In case of complete obstruction of the common bile duct, no significant biliary excretion of the antibiotics occurs, so that biliary...
bactericidal concentrations cannot be achieved\[6,7\]. However, recently a sufficient biliary concentration of the fluoroquinolone moxifloxacin in patients with obstructive cholangitis was reported\[9\]. Because bacteremia may progress to sepsisemia, a high level of serum concentrations of the antibiotic agents is also important for the treatment of biliary tract infections. Although acute cholangitis is a common clinical problem associated with a high level of morbidity and mortality, there is no standardized approach for therapy of this disease. The selection of antibacterial agents is based on the severity of the disease, the expected biliary pathogens or the activity of antibacterial agents against the isolated bacteria from blood or bile cultures. Broad spectrum antibiotics, active against gram negative and gram positive organisms, are the preferred treatment\[8-11\]. Therefore, in case of severe cholangitis, the mostly preferred drug is piperacillin, a broad spectrum penicillin. In a prospective randomised trial including patients with acute cholangitis, equal clinical efficacy was observed with piperacillin alone compared to ampicillin plus tobramycin\[12\]. The combination of piperacillin with the β-lactamase inhibitor sulbactam might be an alternative procedure when the resistance pattern shows a relatively high incidence of ureidopenicillin-resistant \textit{E. coli} or \textit{Klebsiella species}\[3\]. Because of increasing resistance and allergic reactions against penicillin, other antibacterial agents for the treatment of acute cholangitis become necessary. Moxifloxacin is characterized by an enhanced activity against gram positive, gram negative and anaerobic organisms and by a sufficient concentration in the obstructive bile duct. Therefore it may be an alternative antibacterial treatment in patients with acute cholangitis. To address this question, we performed a prospective trial to analyze the in vitro activity of moxifloxacin and piperacillin/sublactam against pathogens isolated from patients with acute cholangitis.

**MATERIALS AND METHODS**

**Study population**

The study included 65 consecutive patients suffering from acute cholangitis who were treated between February 2004 and November 2005 in the Department of Gastroenterology at the Technical University of Munich. All of the following criteria had to be fulfilled: (1) clinical diagnosis of acute cholangitis, (2) elevated cholestasis parameter (bilirubin > 3 mg/dL), (3) elevated infection parameters (leucocytes > 12 G/L, c-reactive protein > 3 mg/dL or fever (> 38.5°C), and (4) age 18-90 years. Exclusion criteria were as follows: (1) primary sclerosing cholangitis, (2) liver cirrhosis, (3) liver transplantation, (4) acquired immunodeficiency syndrome (AIDS), (5) primary immunodeficiency syndrome, (6) therapy with glucocorticoids and other immunosuppressant drugs, (7) leucopenia (leucocytes < 1 G/L), and (8) infection focus other than acute cholangitis.

**Isolation of bacteria**

From all patients included in this study, bile samples for culture were taken. Bile was obtained by endoscopic retrograde cholangiography (ERC) or by percutaneous transhepatic biliary drainage (PTBD). ERC and biliary drainage were performed with a standard videodiodenoscope OlympusTFJ 160-R. Endoscopic sphincterotomy (EST) was conducted using an Olympus papillotome introduced over a Terumo guide wire. At ERC, intraductal bile was collected before contrast agent injection by passing a sterile standard ERC catheter into the obstructed bile duct and aspirating bile into a sterile 10 mL syringe. In case of PTBD, 2-4 mL bile was collected into a sterile 10 mL syringe after penetration of the bile duct with the puncture needle. Thereafter, a percutaneous transhepatic biliary catheter was inserted by the Seldinger technique. Because of the percutaneous placement of this catheter, bile could be obtained all the time in case of fever, chills and increasing infection parameters (leucocytes, c-reactive protein). In 22 febrile patients (temperature > 38.5°C), blood cultures were also obtained. Typically, 10 mL of blood was obtained and transferred into aerobic and anaerobic culture broth (BacTec system, Becton Dickinson, Heidelberg, Germany).

**Microbiological investigation**

In case of positive blood- and/or bile cultures, the in vitro activity of moxifloxacin and piperacillin/sublactam was performed by agar diffusion assay test.

The bile/specimen sampled was examined for aerobic and anaerobic bacteria. In each case, 50-100 μL bile/specimen were both transferred into liquid nutrient media (glucose broth, thioglycolate broth) and spread on solid culture media (Columbia sheep blood agar, chocolate agar, McConkey agar, Schädler anaerobic agar, Schädler KV anaerobic agar, and Sabouroud agar). Subsequently, the culture media were incubated at 37°C. The aerobic cultures were incubated for 48 h, with the first readout taken after 24 h. The anaerobic cultures were monitored for the first time after 48 h and processed further as required. To identify bacteria in the blood, one aerobic and one anaerobic blood culture bottle (BacTec system, Becton Dickinson, Heidelberg, Germany) were each inoculated with 10 mL of venous blood. The blood cultures were incubated at 37°C for 5 d. For control purposes and to exclude failure of automatic detection of the BacTec system each flask was subcultivated under aerobic (chocolate agar in 10% CO\textsubscript{2}) and anaerobic conditions (Schädler anaerobic agar) at the end of the incubation period. Cultivable germs were identified using the ATB, API or VITEK system (BioMérieux, Nütrpingen, Germany). In order to identify antimicrobial inhibitors approximately 10 μL of fluid specimen were placed in the depression of an agar plate containing a suspension of spore forming bacteria. With an antibiotic being present and taking effect in the specimen a clear inhibition zone was to be seen around the point of application. Colony forming units were...
not determined in this study. Antibiotic susceptibility testing was performed using both the disk diffusion test or the MIC test using the VITEK system (BioMérieux, Nürttlingen, Germany) or the Etest system (AB Biodisk, Solna, Sweden) according to the recommendations of the CLSI (Clinical Laboratory Standards Institute; formerly NCCLS/National Committee for Clinical Laboratory Standards).

RESULTS

During the study period from February 2004 to November 2005, a total of 65 consecutive patients with acute cholangitis were included in the current clinical trial. The patients had the following characteristics: mean age 68 ± 12.3 years, 32 male and 33 female, bilirubin 7.9 ± 7.4 mg/dL, alkaline phosphatase 675 ± 510 U/L, γ-glutamyltransferase 697 ± 682 U/L, aspartate aminotransferase 193 ± 300 U/L, alanine aminotransferase 136 ± 147 U/L, leucocytes 16.9 ± 10.7 G/L, C-reactive protein 17.3 ± 9.5 mg/dL (Table 1).

Obstruction of the bile duct was caused by gallstones in 7/65 (10.8%) patients, benign strictures in 16/65 (24.6%) patients and malignant strictures of the biliary tract in 42/65 (64.6%) patients.

Thirty-one out of 65 patients had positive bile- and/or blood cultures. Sixty-three bacterial isolates and 17 different bacterial species were identified from 31 patients. The predominant isolated bacteria were Enterococcus species (26/63), E.coli (13/63), and Klebsiella species (8/63). Thereby, three quarter (74.6%) of the isolated bacteria were obtained from these predominant species, while the remaining quarter (25.4%) consisted of 7 different types. Within the group infected with Enterococcus species, Enterococcus faecalis and Enterococcus faecium were most frequent with 8 and 7 isolates, respectively. Bacteriobilia was documented in 22/65 patients and was polymicrobial in 17 patients (77.3%). Positive blood culture were obtained in 13/65 patients and was polymicrobial in only 1 patient (7.7%).

The resistance pattern of the isolated pathogens was investigated by an in vitro activity assay. Table 2 gives an overview of all bacterial pathogens and their resistance patterns regarding moxifloxacin and piperacillin/sulbactam. In summary, 34.9% (22/63) of all isolated pathogens were resistant, 6.4% (4/63) were intermediate resistant, and 58.7% (37/63) were susceptible to piperacillin/sulbactam. In comparison to these results 36.5% (23/63) of all isolated pathogens were resistant, 9.5% (6/63) intermediate resistance, and 54% (34/63) susceptible to moxifloxacin (Figure 1).

DISCUSSION

Acute cholangitis is an infection of the obstructed biliary tract with a wide spectrum of pathogens. Common microbial populations associated with cholangitis include gram-negative bacteria like E.coli and Klebsiella species. Gram-positive organisms, mainly Enterococcus species and anaerobes, are also found[4-21]. While previous works found E.coli infection in 20.9% and Enterococcus species in 20.9%[17], our current results reveal that the most common isolates are Enterococcus species [41.3% (26/63)], E.coli [20.6% (13/63)] and Klebsiella species [12.7% (8/63)]. In addition to this a lot of other bacterial pathogens were isolated by blood and/or bile cultures (Table 2). Thus, the shift towards the higher rate of Enterococcus species and the high prevalence of Klebsiella infections might be related to the use of wide-spectrum antibiotics used in the past years.

Establishment of biliary drainage is the mainstay of therapy for patients with acute cholangitis. Endoscopic sphincterotomy with subsequent biliary drainage is the therapy of choice, but in case of therapy failure percutaneous transhepatic bile drainage is an alternative method for biliary drainage[22-24]. Nevertheless, once endoscopic and/or percutaneous transhepatic procedures have been performed, the spectrum of bacterial infection might change, and increased frequency of mixed infections has been reported[17]. Our current data are in line with this observation and reveal polymicrobial infections of the biliary tract in 17 out of 22 patients.

Overall, our results indicate that bacterial pathogens could only be isolated in 48% of the patients. Antibiotic treatment has to start early during the infectious process. In clinical practice, it is not possible to isolate bacterial pathogens in all patients and the time to receive the resistance pattern creates a delay of several days. Therefore, knowledge of bacterial spectrum and resistance pattern of antimicrobial agents is essential for the treatment of patients suffering from acute cholangitis.
Finally, it has to be mentioned that in patients with an obstructed biliary tract, the biliary excretion of several antibiotic agents is limited. Recently, it was reported that moxifloxacin, a fluoroquinolone, can reach clinically significant concentrations in obstructed biliary tract. Therefore it may be a superior treatment in patients with acute cholangitis that suffer from biliary obstruction. Until now, no data about antimicrobial activity of moxifloxacin against pathogens of acute cholangitis exists. Therefore, we isolated pathogens from patients with acute cholangitis and analyzed the in vitro activity of moxifloxacin and piperacillin/sulbactam. Our data show a comparable in vitro activity of moxifloxacin and piperacillin/sulbactam in patients with acute cholangitis. Kisielich et al. reported a resistance rate of 71.8% (28/39) for piperacillin and 76.7% (33/43) for ampicillin (both without β-lactamase inhibitors) in bacteria isolated from obstructed biliary tract during endoscopic retrograde cholangiography. In this study, the resistance rate for other fluoroquinolones ciprofloxacin and levofloxacin was 19.0% (8/42) and 2.2% (1/45), respectively. In agreement with these results, 96% (122/127) sensitivity to ciprofloxacin and 29% (37/127) sensitivity to ampicillin was reported in other studies.

The in vitro benefit of fluoroquinolones in patients with biliary tract infections was investigated in several clinical trials. Karachilios et al. performed a prospective, randomized trial with ofloxacin in one, and ceftriaxone in the other group. The clinical cure or improvement of clinical symptoms was the same in both groups. In another prospective randomized trial, an adequate clinical benefit was shown for ciprofloxacin mono therapy in comparison to a triple therapy with ceftazidime, ampicillin and metronidazole. Also levofloxacin, a newer enantiomer of ofloxacin showed an adequate clinical effect when compared to ceftriaxone. In this prospective randomized trial, patients of both study groups received metronidazole additionally.

Although, moxifloxacin and piperacillin/sulbactam appears to have a comparable in vitro activity against pathogens of acute cholangitis, moxifloxacin may have a clinical benefit due to its extensive biliary excretion in obstructed biliary tract. Randomized clinical trials should be performed to evaluate clinical outcome of moxifloxacin in patients with acute cholangitis.

**Table 2 Resistance pattern for moxifloxacin and piperacillin/sulbactam in all pathogens**

| Pathogens               | Moxifloxacin | Piperacillin/Sulbactam |
|-------------------------|--------------|------------------------|
|                         | Susceptible  | Intermediate | Resistant | Susceptible | Intermediate | Resistant |
| Enterococcus species    | 9            | 4           | 13        | 16          | 1           | 9         |
| Enterococcus NS         | 2            | 4           | 2         | 7           | 1           | 1         |
| Enterococcus faecium    | 1            | 7           | 2         | 1           | 3           | 5         |
| Enterococcus faecalis   | 4            | 3           | 5         | 2           |             |           |
| Enterococcus casseliflavus | 2          |             | 1         | 2           |             |           |
| Enterococcus gallinarum |             |             |           |             |             |           |
| *Escherichia coli*      | 8            | 1           | 4         | 11          | 2           |           |
| Klebsiella species      | 5            | 1           | 2         | 4           | 1           | 3         |
| Klebsiella pneumoniae   | 3            | 1           | 2         | 2           | 1           | 3         |
| Klebsiella oxytoxica    | 2            | 2           |           |             |             |           |
| Enterobacter species    | 5            | 3           |           | 2           |             |           |
| Enterobacter cloacae    | 3            |             |           |             |             |           |
| Enterobacter NS         | 2            |             |           |             |             |           |
| Pseudomonas aeruginosa  | 2            |             |           |             |             |           |
| *Aeromonas* species     | 1            |             |           |             |             |           |
| *Aeromonas* hydrophila/caviae | 1       |             |           |             |             |           |
| *Aeromonas* NS          | 1            | 1           |           |             |             |           |
| *Citrobacter freundii*  | 2            |             |           |             |             |           |
| Coagulase neg. *Staphylococcus* | 2     |             |           |             |             |           |
| Gram negative rod NS    | 1            |             |           |             |             | 1         |
| Streptococcus anginosus  | 1            |             |           |             |             | 1         |

NS: Not specified.

**COMMENTS**

**Background**

Cholangitis is a frequent and potentially serious complication in patients with bile duct obstruction. Biliary decompression by endoscopic intervention and selection of appropriate antibiotics are crucial for therapy of these patients. The use of broad-spectrum penicillin is generally accepted. Because of increasing resistance and allergic reactions against penicillin, other antibacterial agents for the treatment of acute cholangitis are essential. Moxifloxacin is characterized by an enhanced activity against gram-positive and -negative anaerobic organisms as well as a sufficient concentration in the obstructive bile duct. Therefore it may be an alternative antibacterial treatment for acute cholangitis.

**Research frontiers**

To our knowledge, no study exists investigating the in vitro activity of moxifloxacin against pathogens isolated from patients with acute cholangitis. The current study was designed to analyze the in vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis.

**Innovations and breakthroughs**

The predominant pathogens isolated from patients with acute cholangitis were *Enterococcus species*, *E.coli* and *Klebsiella species*. A comparable in vitro activity of moxifloxacin and piperacillin/sulbactam was observed for *E.coli* and *Klebsiella species*. In contrast, *Enterococcus species* had higher resistances towards moxifloxacin. Overall bacteria showed antibiotic resistances of 34.9% for piperacillin/sulbactam and 36.5% for moxifloxacin.

**Applications**

These data suggest that moxifloxacin can be used as an alternative antibiotic therapy in patients with cholangitis that show allergic reactions to piperacillin/sulbactam. Additionally, due to the extensive excretion of moxifloxacin in the obstructed biliary tract it may have a clinical advantage compared to other antibiotics.
standard therapy. Randomized controlled trials should be performed to evaluate the clinical outcome of moxifloxacin in patients with acute cholangitis.

**Terminology**

Acute cholangitis with the triad of jaundice, fever and abdominal pain: was first described by Charcot in 1877. It is a frequent and potentially serious complication in patients with bile duct obstruction due to ductal stones, benign and malignant bile duct strictures. Bile duct obstruction leads to a raised intrabiliary pressure with cholangiovenous reflux and bacteremia, which may induce sepsis.

**Peer review**

This manuscript evaluates the relative resistance of bacterial cultures isolated from patients suffering acute cholangitis to piperacillin/sulbactam (the current standard therapy). Randomized controlled trials should be performed to evaluate the clinical outcome of moxifloxacin in patients with acute cholangitis. Clin Infect Dis 1992; 15: 615-628

**REFERENCES**

1. **Leung JW**, Ling TK, Chan RC, Cheung SW, Lai CW, Sung JJ, Chung SC, Cheng AF. Antibiotics, biliary sepsis, and bile duct stents. *Gastrointest Endosc* 1994; 40: 716-721
2. **Westphal JE**, Brogard JM. Biliary tract infections: a guide to drug treatment. *Drugs* 1999; 57: 81-91
3. **Lai EC**, Mok FP, Tan ES, Lo CM, Fan ST, You KT, Wong J. Endoscopic biliary drainage for severe acute cholangitis. *N Engl J Med* 1992; 326: 1582-1586
4. **Audisio RA**, Morosi C, Boffetti F, Cozzi G, Bellomi M, Pisanì P, Pestalozza A, Gennari L, Severini A. The outcome of cholangitis after percutaneous biliary drainage in neoplastic jaundice. *HPB Surg* 1995; 6: 287-293
5. **Jain MK**, Jain R. Acute bacterial cholangitis. *Curr Treat Options Gastroenterol* 2006; 9: 113-121
6. **Leung JW**, Chan RC, Cheung SW, Sung JY, Chung SC, French GL. The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime. *J Antimicrob Chemother* 1990; 25: 399-406
7. **van den Hazel SJ**, de Vries XH, Speelman P, Dankert J, Tytgat GN, Huijbregts K, van Leeuwen DJ. Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. *Antimicrob Agents Chemother* 1996; 40: 2658-2660
8. **Schwab D**, Grauer M, Hahn EG, Muhldorfer S. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. *Ainmt Pharmacoal Ther* 2005; 22: 417-422
9. **Tanaka A**, Takada T, Kawarada Y, Nimura Y, Yoshida M, Miura F, Hirota M, Wada K, Mayumi T, Gomi H, Solomkin JS, Strasberg SM, Pitt HA, Belghiti J, de Santibanes E, Padbury R, Chen MF, Belfi G, Kor CG, Hilvano SC, Fan ST, Liau KH. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. *J Hepatobiliary Pancreat Surg* 2007; 14: 59-67
10. **van den Hazel SJ**, Speelman P, Tytgat GN, Dankert J, van Leeuwen DJ. Role of antibiotics in the treatment and prevention of acute and recurrent cholangitis. *Clin Infect Dis* 1994; 19: 279-286
11. **Sinanan MN**. Acute cholangitis. *Infect Dis Clin North Am* 1992; 6: 571-599
12. **Thompson JE** Jr, Pitt HA, Doty JE, Coleman J, Irving C. Broad spectrum penicillin as an adequate therapy for acute cholangitis. *Surg Gynecol Obstet* 1990; 171: 275-282
13. **Chamberland S**, L’Ecuyer J, Lessard C, Bernier M, Provencher P, Bergeron MG. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group. *Clin Infect Dis* 1992; 15: 615-628
14. **Nielsen ML**, Justesen T. Anaerobic and aerobic bacteriological studies in biliary tract disease. *Scand J Gastroenterol* 1976; 11: 437-446
15. **England DM**, Rosenblatt JE. Anaerobes in human biliary tracts. *J Clin Microbiol* 1977; 6: 494-498
16. **Maddocks AC**, Hilson GR, Taylor R. The bacteriology of the obstructed biliary tree. *Ann R Coll Surg Engl* 1973; 52: 316-319
17. **Lorenz R**, Herrmann M, Kasses AM, Lehn N, Neuhaus H, Classen M. Microbiological examinations and in-vitro testing of different antibiotics in therapeutic endoscopy of the biliary system. *Endoscopy* 1998; 30: 708-712
18. **Brook I**. Aerobic and anaerobic microbiology of biliary tract disease. *J Clin Microbiol* 1989; 27: 2373-2375
19. **Leung JW**, Liu YL, Lau GC, Chan RC, Lee AC, Ling TK, Cheng AF. Bacteriologic analyses of bile and brown pigment stones in patients with acute cholangitis. *Gastrointest Endosc* 2001; 54: 340-345
20. **Shimada K**, Noro T, Inamatsu T, Urayama K, Adachi K. Bacteriology of acute obstructive suppurative cholangitis of the aged. *J Clin Microbiol* 1981; 14: 522-526
21. **Flores C**, Magulnik I, Hadlich E, Goldani LZ. Microbiology of choledochal bile in patients with choledocholithiasis admitted to a tertiary hospital. *J Gastroenterol Hepatol* 2003; 18: 333-336
22. **Lai EC**, Mok FP, Tan ES, Lo CM, Fan ST, You KT, Wong J. Endoscopic biliary drainage for severe acute cholangitis. *N Engl J Med* 1992; 326: 1582-1586
23. **Leung JW**, Chung SC, Sung JJ, Banez VP, Li AK. Urgent endoscopic drainage for acute suppurative cholangitis. *Lancet* 1989; 1: 1307-1309
24. **Nelsen KM**, Kastan DJ, Shetty PC, Burke MW, Sharma RP, Venugopal C. Utilization pattern and efficacy of nonsurgical techniques to establish drainage for high biliary obstruction. *J Vasc Interv Radiol* 1996; 7: 751-756
25. **Keighley MR**, Drysdale RB, Quaasraish AH, Burdon DW, Alexander-Williams J. Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum. *Gut* 1976; 17: 495-500
26. **Kiesslich R**, Hoffelder M, Will D, Hahn M, Nafe B, Gentisariotis R, Daniello S, Maeurer M, Jung M. [Interventional ERCP in patients with cholestasis. Degree of biliary bacterial colonization and antibiotic resistance] *Z Gastroenterol* 2001; 39: 995-992
27. **Rerknimitr R**, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S. Microbiology of bile in patients with cholangitis with or without plastic biliary endoprosthesis. *Gastrointest Endosc* 2002; 56: 885-889
28. **Karachalios GN**, Nasiopoulos DD, Bourlouinou PK, Reppa A. Treatment of acute biliary tract infections with ofloxacin: a randomized, controlled clinical trial. *Int J Clin Pharmacol Ther* 1996; 34: 555-557
29. **Sung JJ**, Lyon DJ, Suen R, Chung SC, Co AL, Cheng AF, Leung JW, Li AK. Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. *J Antimicrob Chemother* 1995; 35: 855-864
30. **Kiesslich R**, Will D, Hahn M, Nafe B, Gentisariotis R, Maurer M, Jung M. [Ceftriaxone versus Levofloxacin for antibiotic therapy in patients with acute cholangitis] *Z Gastroenterol* 2003; 41: 5-10

S-Editor Li JN  L-Editor Alpini GD  E-Editor Ma WH

www.wjgnet.com